Evolus to Report Second Quarter 2020 Financial Results and Provide a Business Update on Monday, August 10, 2020GlobeNewsWire • 07/27/20
Evolus Provides Update on United States International Trade Commission (USITC) CaseGlobeNewsWire • 07/06/20
Evolus' (EOLS) CEO David Moatazedi on Q1 2020 Results - Earnings Call TranscriptSeeking Alpha • 05/12/20
Evolus, Inc. (EOLS) CEO David Moatazedi on Q4 2019 Results - Earnings Call TranscriptSeeking Alpha • 02/25/20
Positive Results from Phase III, Split-Face, Head-to-Head Study Comparing OnabotulinumtoxinA and PrabotulinumtoxinA in the Treatment of Crow’s Feet Lines Published in Dermatologic SurgeryGlobeNewsWire • 01/27/20
Evolus, Inc. (EOLS) CEO David Moatazedi on Q3 2019 Results - Earnings Call TranscriptSeeking Alpha • 11/04/19
Evolus and Clarion Medical Technologies Announce First Shipment of Nuceiva™ (prabotulinumtoxinA) to Customers in CanadaGlobeNewsWire • 10/16/19
Evolus Announces Successful Completion of the Jeuveau® Experience Treatment (J.E.T) ProgramGlobeNewsWire • 09/04/19
Evolus, Inc. (EOLS) CEO David Moatazedi on Q2 2019 Results - Earnings Call TranscriptSeeking Alpha • 08/12/19
Evolus, Inc. (EOLS) CEO David Moatazedi on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha • 05/01/19